Archive: August 2022
Feature
Novel Therapies for Patients With Inflammatory Bowel Disease
Abstract: The implementation of biologic therapy has improved the treatment and clinical course of patients with inflammatory bowel disease since the initial approval of infliximab for […]
Feature
Review of Updated Hepatitis B Vaccine Recommendations and Potential Challenges With Implementation
Abstract: Hepatitis B virus (HBV) infection is a vaccine-preventable disease associated with substantial morbidity and mortality. Although safe and effective hepatitis B vaccines are available, an […]
Letter From the Editor
Letter From the Editor: Emerging Treatments for Inflammatory Bowel Disease
Which therapies look promising as future therapeutic options for the treatment of patients with inflammatory bowel disease (IBD)? A review article in this month’s issue of […]
NASH
Alcohol Consumption and Nonalcoholic Steatohepatitis/Nonalcoholic Fatty Liver Disease
G&H Are there notable differences between alcohol-related liver disease and nonalcoholic steatohepatitis/nonalcoholic fatty liver disease other than the consumption of alcohol? ML Histologically, alcohol-related liver disease […]
Advances in IBD
Histologic Healing in Inflammatory Bowel Disease
G&H How can histologic healing be best defined in patients with inflammatory bowel disease? BC This is a complex question to answer. Despite increasing evidence suggesting […]
HCC in Focus
The Use of Albumin-Bilirubin Grade in Patients With Hepatocellular Carcinoma
G&H How and why did albumin-bilirubin grade come to be used in patients with hepatocellular carcinoma? PG Over a decade ago, the SHARP trial demonstrated the […]
Advances in GERD
Overview of Refractory Gastroesophageal Reflux Disease
G&H How prevalent is refractory gastroesophageal reflux disease? RN In published reports, the prevalence of refractory gastroesophageal reflux disease (GERD) despite proton pump inhibitor (PPI) therapy […]